Finasteride in the treatment of patients with benign prostatic hyperplasia: A review

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 535-545

  Smith, Angela B ^a   Carson, Culley C ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

5 reductase inhibitor; Finasteride; Prostatic hyperplasia

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN; ANDROSTANOLONE; DOXAZOSIN; FINASTERIDE; HEMOGLOBIN; LOW DENSITY LIPOPROTEIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TERAZOSIN; TESTOSTERONE;

BONE TURNOVER; CANCER RISK; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; NONHUMAN; ORGAN SIZE; ORTHOSTATIC HYPOTENSION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE SIZE; REVIEW; RISK REDUCTION; SEXUAL DYSFUNCTION; SIDE EFFECT; SYMPTOM; TREATMENT OUTCOME; URINE RETENTION;

EID: 75849135695     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Emberton M, Cornel EB, Bassi PF, Fourcade RO, Gomez JM, Castro R. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract. 2008;62:1076-1086.
2. Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem. 1994;63:25-61.
3. Jenkins EP, Andersson S, Imperato-McGinley J, Wilson JD, Russell DW. Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase. J Clin Invest. 1992;89:293-300.
4. Carson C, 3rd, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology. 2003;61:2-7.
5. Norman RW, Coakes KE, Wright AS, Rittmaster RS. Androgen metabolism in men receiving finasteride before prostatectomy. J Urol. 1993;150:1736-1739.
6. Anderson JB, Roehrborn CG, Schalken JA, Emberton M. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol. 2001;39:390-399.
7. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338:557-563.
8. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992;327:1185-1191.
9. Campbell MF, Wein AJ, Kavoussi LR. Campbell-Walsh Urology. Alan J. Wein AJ, editor-in-chief, Kavoussi LR, et al. eds. 9th ed. Philadelphia: W.B. Saunders; 2007.
10. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group. Prostate. 1993;22:291-299.
11. Andersen JT, Ekman P, Wolf H, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology. 1995;46:631-637.
12. Boyarsky S, Jones G, Paulson DF, Prout GR Jr. A new look at bladder neck obstruction by the food and drug administration regulators: guide lines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourin Surg. 1976;68:29-32.
13. Bolognese JA, Kozloff RC, Kunitz SC, Grino PB, Patrick DL, Stoner E. Validation of a symptoms questionnaire for benign prostatic hyperplasia. Prostate. 1992;21:247-254.
14. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 1994;43:284-292; discussion 92-94.
15. Hudson PB, Boake R, Trachtenberg J, et al. Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group. Urology. 1999;53:690-695.
16. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: metaanalysis of randomized clinical trials. Urology. 1996;48:398-405.
17. Tammela TL, Kontturi MJ. Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia. J Urol. 1993;149:342-344.
18. Tammela TL, Kontturi MJ. Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia. J Urol. 1995;154:1466-1469.
19. Puchner PJ, Miller MI. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. J Urol. 1995;154:1779-1782.
20. Miller MI, Puchner PJ. Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long-term follow-up. Urology. 1998;51:237-240.
21. Carlin BI, Bodner DR, Spirnak JP, Resnick MI. Role of finasteride in the treatment of recurrent hematuria secondary to benign prostatic hyperplasia. Prostate. 1997;31:180-182.
22. Foley SJ, Soloman LZ, Wedderburn AW, et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol. 2000;163:496-498.
23. Donohue JF, Hayne D, Karnik U, Thomas DR, Foster MC. Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks. BJU Int. 2005;96:1319-1322.
24. Memis A, Ozden C, Ozdal OL, Guzel O, Han O, Seckin S. Effect of finasteride treatment on suburethral prostatic microvessel density in patients with hematuria related to benign prostate hyperplasia. Urol Int. 2008;80:177-180.
25. Ozdal OL, Ozden C, Benli K, Gokkaya S, Bulut S, Memis A. Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study. Prostate Cancer Prostatic Dis. 2005;8:215-218.
26. Mondaini N, Gontero P, Giubilei G, et al. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med. 2007;4:1708-1712.
27. Moinpour CM, Darke AK, Donaldson GW, et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99:1025-1035.
28. Amory JK, Anawalt BD, Matsumoto AM, et al. The effect of 5 alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. J Urol. 2008;179:2333-2338.
29. Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, Mualeki A. Finasteride induced depression: a prospective study. BMC Clin Pharmacol. 2006;6:7.
30. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med. 1996;335:533-539.
31. Lepor H, Williford WO, Barry MJ, Haakenson C, Jones K. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. J Urol. 1998;160:1358-1367.
32. Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003;61:119-126.
33. Debruyne FM, Jardin A, Colloi D, et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol. 1998;34:169-175.
34. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387-2398.
35. Kaplan SA, McConnell JD, Roehrborn CG, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol. 2006;175:217-220; discussion 20-1.
36. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5 alpha-reductase inhibitor dutasteride. Eur Urol. 2003;44:461-466.
37. Guess HA, Heyse JF, Gormley GJ. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate. 1993;22:31-37.
38. Andriole GL, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology. 1998;52:195-201; discussion 2.
39. Thompson CA. Finasteride may prevent prostate cancer. Am J Health Syst Pharm. 2003;60:1511, 1515.
40. Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99:1375-1383.
41. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Jr, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila Pa). 2008;1:174-181.
42. Lucia MS, Darke AK, Goodman PJ, et al. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila Pa). 2008;1:167-173.
43. Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS. Five-alpha-reductase Inhibitors for prostate cancer prevention. Cochrane Database Syst Rev. 2008:CD007091.
44. Kramer BS, Hagerty KL, Justman S, et al. Use of 5 alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Urol. 2009;181:1642-1657.
45. Johansen TE, Istad JA. Long-term cost analysis of treatment options for benign prostatic hyperplasia in Norway. Scand J Urol Nephrol. 2007;41:124-131.
46. Lafuma ASTP, Briand Y, Guelfucci F. Cost-efficacy of finasteride, doxazosin, and the combination of both in the treatment of benign prostatic hyperplasia (BPH) in france based on the mtops study. Value Health. 2006;9:A386-A387.
47. Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Coste-ffectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer. 2008;112:1058-1065.